Lung Cancer Journal
@LungCaJournal
Followers
2K
Following
248
Media
65
Statuses
156
Journal on clinical, translational & basic science of lung & chest malignancies #LCSM. Affiliated with @myESMO, @BTOGORG, @etop_ibcsg and ILCCO
Amsterdam, the Netherlands
Joined February 2021
Opinions are those of the editorial team. Retweets are not endorsements. Tweets by @etop_ibcsg & @BTOGORG
0
0
1
Retrospective review of patients with lung cancer treated at National Cancer Center Hospital in Japan @LungCaJournal over the past 20 years shows steady survival gains: 2001-05 mOS 10.7m, 2006-10 OS 14.1m, 2011-15 OS 16.5m, and 2016-21 OS 25.5m. https://t.co/B0mZlteIe8
lungcancerjournal.info
Over the past few decades, many anticancer drugs have been developed for lung cancer; however, they remain the leading cause of cancer-related death worldwide [1]. The discovery of novel therapies...
1
18
48
Report on NGS in squamous NSCLC @LungCaJournal from Dr. @Joshua_Reuss et al. Detected actionable genomic alterations in 22.2% of patients with squamous NSCLC and no history of smoking including #EGFR and #MET. In those with prior smoking, AGAs in 2.4%. https://t.co/O9NQj5J4jJ
lungcancerjournal.info
Comprehensive next-generation sequencing (NGS) has become paramount to the appropriate work-up and management of advanced non-small cell lung cancer (NSCLC). The detection of actionable genomic...
2
32
89
Analysis of ctDNA in #HER2 NSCLC receiving pyrotinib and apatinib (PATHER2 study) @LungCaJournal. Clearance of ctDNA associated with longer PFS and OS trend. At resistance, chromatin remodeling pathway genes often mutated, on-target resistance uncommon. https://t.co/KSaBPwJSZF
lungcancerjournal.info
Human epidermal receptor tyrosine kinase 2 (HER2/ERBB2) mutation is recognized as a critical driver of non-small cell lung cancer (NSCLC), occurring in approximately 2 %–3% of patients [1–3]. These...
1
9
30
Small report on #SCLC subtypes @LungCaJournal. Using IHC, differences in subtypes between primary tumors and brain metastases and notable heterogeneity (mixed subtypes) throughout. Matched samples showed changes in subtypes over time. https://t.co/LRzhHpVDwg
lungcancerjournal.info
Small cell lung carcinoma (SCLC), which accounts for 15 % of all lung cancers, is characterised by an unfavourable prognosis and early metastasis formation [1]. Platinum-based chemotherapy is still...
3
10
40
We are pleased to announce that our journal now accepts *Trial in Progress (TiP) papers*, including ongoing phase II and III trials registered with NCI's Clinical Trials Reporting Program. All submission guidelines are available here 🔗 https://t.co/Dfd0JXlFDv
3
9
33
🚨📝 A pragmatic guide for management of adverse events associated with lorlatinib Link here 👉 https://t.co/7UELfAmYGQ
#LCSM @ALKPositiveinc
lungcancerjournal.info
Anaplastic lymphoma kinase (ALK) gene rearrangements are present in 2% to 7% of the non-small cell lung cancer (NSCLC) patient population [1–3]. Identification of ALK gene rearrangements in NSCLC is...
1
17
35
Outcomes with chemo-immunotherapy by #KRAS, STK11, and KEAP1 across PDL1 strata @LungCaJournal. KRAS mt enriched in PDL1 high but KRAS with co-mutations in STK11 and KEAP1 enriched in PDL1 negative. Poor OS in KRAS mt with PDL1 0% driven by STK11/KEAP1. https://t.co/U7d7VXDRcE
lungcancerjournal.info
KRAS mutations(m) are the most common oncogenic alterations in NSCLC, occurring in 20–40 % of lung adenocarcinomas [1–3]. While KRAS has been historically considered undruggable, two KRAS G12C...
1
37
109
Current Trial Report on the TARGET trial TARGET is a phase II, open-label, single-arm study of 5-year adjuvant #osimertinib in completely resected EGFR-mutated stage II to IIIB NSCLC Primary endpoint: investigator-assessed DFS at 5 years More: https://t.co/YRR6BbC2J1
0
10
16
Happy to see our work on KL-6/MUC1 in pleural meso now out in @LungCaJournal: ➤ KL-6 lvls in pleural eff were diagnostic in 2 indep cohorts of pts with pleural meso. ➤⬆️KL-6 lvls and ⬆️MUC1 mRNA expression were associated with⬆️patient outcome. 👉 https://t.co/4lFwvOPabh
1
1
8
💡#LCSM a new review by @FordePatrick and colleagues, not to be missed!! Neoadjuvant immunotherapy in NSCLC!!! 🚨 https://t.co/gGFd5fAqXe
New review @LungCaJournal from Dr. @FordePatrick and team on neoadjuvant immunotherapy for resectable NSCLC, outlining rationale, current options, and future directions. https://t.co/1rGwVzGljZ
0
4
11
🆕Just out in @LungCaJournal this interesting editorial by @DrJNaidoo & . @FCortiula discussing the role of neoadjuvant Osimertinib in resectable NSCLC, harbouring EGFR mutations #LCSM Here the link: https://t.co/rmZjJgVALv
0
16
44
🚨🆕 Just out in @LungCaJournal this review by @MarianaBrandao0 et al, discussing “Systemic treatment & radiotherapy for pts with NSCLC & #HIV infection” #LCSM Find it here 🔗 https://t.co/oHa6Ajwfwu
2
11
26
The European Lung Cancer Congress is ready to start in a few of days *Official hashtag: #ELCC23 👈🏻
1
10
48
🚨just out in @LungCaJournal this important review lead by @MartinReck2 discussing the role of anti-angiogenic agents for the treatment of resistant NSCLC: rationale, recent updated and perspectives #LCSM 🔗 https://t.co/t846xc1qlq
0
13
26
TROP2 expression and SN38 antitumor activity in malignant pleural #mesothelioma cells provide a rationale for antibody-drug conjugate therapy #LCMS #meso
https://t.co/KKx25wRYyj
0
8
27
Age-period-cohort effect on lung cancer mortality in Spain, 1982-2021 #LCSM 🇪🇸 https://t.co/q3zfzwSRu4
0
3
5
🚨just out in @LungCaJournal MET Alterations in Advanced NSCLC @metcrusaders #LCSM
https://t.co/vyjv9zr5zc
0
12
18
Have you registered for #BTOG23 yet? Our fantastic programme of expert speakers is available on our website. Join us in Belfast for this event that's not to be missed by anyone working in the field of #LungCancer
https://t.co/40aEPSaF7f
0
5
17
🆕🗞️Out in the @LungCaJournal an excellent review investigating *Primary endpoints to assess the efficacy of novel therapeutic approaches in EGFR-mutated, surgically resectable NSCLC #LCSM
https://t.co/asQRMkorbK
0
14
34